SCHEMBL12100255

SCHEMBL12100255

COC(=O)c1ccc2nc(-c3ccc(N)c([N+](=O)[O-])c3)c(N3CCC[C@@H]3C)nc2c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 3/20 0.38
MAPT P10636 3/20 0.38
SYK P43405 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
S1PR1 P21453 1/20 0.37
ERN1 O75460 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
OPRK1 P41145 1/20 0.36
KDM4E B2RXH2 1/20 0.36
THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12100250 1.00 TP53 (0.39) TP53ALDH1A1HPGDSMN1; SMN2POLB
SCHEMBL12100793 0.91 LMNA (0.44) TP53ALDH1A1HPGDSMN1; SMN2POLB
SCHEMBL12100794 0.91 LMNA (0.44) TP53ALDH1A1HPGDSMN1; SMN2POLB
SCHEMBL12100194 0.90 SYK (0.41) ALDH1A1HPGDSMN1; SMN2MAPTSYK
SCHEMBL12100191 0.90 SYK (0.41) ALDH1A1HPGDSMN1; SMN2MAPTSYK
SCHEMBL12687311 0.83 SYK (0.43) ALDH1A1HPGDMAPTSYKERN1
SCHEMBL12100788 0.82 SYK (0.41) ALDH1A1HPGDMAPTSYKERN1
SCHEMBL12100787 0.82 SYK (0.41) ALDH1A1HPGDMAPTSYKERN1
SCHEMBL12093874 0.82 NAMPT (0.48) MAPT
SCHEMBL12100397 0.82 NAMPT (0.48) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2681207-B1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2016-12-28 EP disclosed
US-8912188-B2 Substituted quinoxaline carboxylic acids for the inhibition of PASK BIOENERGENIX, LLC (US) 2014-12-16 US disclosed
US-8912188-B2 Substituted quinoxaline carboxylic acids for the inhibition of PASK BIOENERGENIX, LLC (US) 2014-12-16 US disclosed
US-8912188-B2 Substituted quinoxaline carboxylic acids for the inhibition of PASK BIOENERGENIX, LLC (US) 2014-12-16 US disclosed
US-20120232056-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-09-13 US disclosed
US-20120232056-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-09-13 US disclosed
WO-2012119046-A2 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK BIOENERGENIX (US) 2012-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232056-A1 HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK PASK, PDXK, PANK2 TP53 1469/4885ALDH1A1 3714/4885HPGD 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.